Montelukast Ratiopharm (Montelukast Sodium)

Montelukast, the active ingredient in Montelukast Ratiopharm, is a leukotriene receptor antagonist presented as an oral tablet for oral use. Approved in the European Union, it is employed to control asthma, exercise‑induced bronchoconstriction, and allergic rhinitis in adults and children.

GNH USA supplies Montelukast Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to relieve airway and nasal symptoms. - Asthma: improves long‑term control and reduces exacerbations. - Exercise‑induced bronchoconstriction: prevents narrowing of airways during physical activity. - Allergic rhinitis: alleviates nasal congestion, sneezing and itchy eyes.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Upper respiratory tract infection: transient symptoms. - Abdominal pain or dyspepsia. - Cough: occasional dry cough.

Serious or Rare Side Effects: - Mood changes or depression: monitor for suicidal thoughts. - Allergic reactions: rash, pruritus, or angioedema. - Hepatotoxicity: rare elevation of liver enzymes. - Stevens‑Johnson syndrome: extremely rare severe skin reaction.

Before prescribing Montelukast, consider the following safety measures. - Pregnancy: safety category unknown; weigh potential benefits against risks. - Breastfeeding: assess infant exposure and possible effects. - Liver impairment: use with caution; monitor hepatic function. - Concomitant psychiatric conditions: observe for mood alterations. - Drug interactions: review patient’s medication list for potential conflicts. - Store at ambient temperature: keep below 25°C, retain in original packaging and protect from moisture.

Montelukast may interact with other medicines; awareness helps avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Phenobarbital or rifampicin: may lower montelukast plasma levels. - Strong CYP3A4 inducers: can reduce therapeutic effect.

Moderate Interactions (Monitor Closely): - Warfarin: occasional alteration of INR; monitor coagulation. - Theophylline: potential additive bronchodilator effect. - Antidepressants (SSRIs, SNRIs): monitor for mood changes.